Death or stroke · people with symptomatic intracranial artery stenosis
Endovascular therapy plus conventional medical treatment probably leads to higher death or stroke compared with conventional medical treatment alone (moderate certainty).
1 finding from 1 review
Long‐term ipsilateral stroke · people with symptomatic intracranial artery stenosis
Endovascular therapy plus conventional medical treatment probably leads to higher ipsilateral stroke compared with conventional medical treatment alone (moderate certainty).
1 finding from 1 review
Type of recurrent event · people with symptomatic intracranial artery stenosis
Endovascular therapy plus conventional medical treatment showed no clear difference in type of recurrent event compared with conventional medical treatment alone (moderate certainty).
1 finding from 1 review
Death · people with symptomatic intracranial artery stenosis
Endovascular therapy plus conventional medical treatment may leads to higher death compared with conventional medical treatment alone (low certainty).
1 finding from 1 review
Dependency · people with symptomatic intracranial artery stenosis
Endovascular therapy plus conventional medical treatment showed no clear difference in dependency compared with conventional medical treatment alone (moderate certainty).
1 finding from 1 review
Restenosis (≥ 50%) · people with symptomatic intracranial artery stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with symptomatic intracranial artery stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or stroke · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in 30‐day post‐randomisation death/stroke compared with medical treatment alone (low certainty).
1 finding from 1 review
Fatal/non‐fatal stroke in the territory of the treated vertebral artery stenosis(assessed after 30 days post‐randomisation to completion of · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in fatal/non‐fatal stroke in the territory of the treated vertebral… compared with medical treatment alone (moderate certainty).
1 finding from 1 review
Stroke (ischaemic or haemorrhagic)Median · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in stroke (ischaemic or haemorrhagic)Median compared with medical treatment alone (moderate certainty).
1 finding from 1 review
DeathMedian · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in deathMedian compared with medical treatment alone (low certainty).
1 finding from 1 review
Stroke or TIAMedian · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in stroke or TIAMedian compared with medical treatment alone (moderate certainty).
1 finding from 1 review
Restenosis ‐ not measured · people with vertebral artery stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Good functional outcome ‐ not measured · people with vertebral artery stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Changes of fatigue scores from baseline to after treatment (assessed by energy/fatigue scale from the Medical Outcomes Study) · people with stroke not necessarily having fatigue
1 finding from 1 review
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review
Time‐to‐event analyses for composite of recurrent stroke or TIA · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for composite of recurrent stroke or TIA compared with medical therapy (low certainty).
1 finding from 1 review
Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for composite of recurrent stroke or TIA… compared with medical therapy (low certainty).
1 finding from 1 review
CI: Confidence interval;HR: hazard ratio · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) stratified by the type of device ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review